Zevra Therapeutics (ZVRA) AI Stock Analysis

• Market Cap: $614.05M
• Dividend Yield: N/A
• Average Volume (3M): 1.10M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: 44.92%
• EPS Growth: -40.06%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 54,679,640
• 10 Day Avg. Volume: 1,287,663
• 30 Day Avg. Volume: 1,096,797
• PEG Ratio: -0.51
• Price to Book (P/B): 16.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.23
• Enterprise Value/Market Cap: 1.18
• Enterprise Value/Revenue: 6.41
• Enterprise Value/Gross Profit: 22.62
• Enterprise Value/Ebitda: -2.63
• 1Y Price Target: $24.17
• Price Target Upside: 115.23% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 60 Neutral
• Price Target: $12.00 ▲(6.86%Upside)

Zevra Therapeutics' overall stock score reflects significant financial challenges, primarily negative profitability and cash flow issues. However, the positive technical indicators and strategic progress in the earnings call provide a more optimistic outlook. The valuation concerns due to the negative P/E ratio and lack of dividend yield slightly dampen the score.

Positive Factors

Financial Performance

Zevra reported net revenue of $20.4M, beating consensus and forecast, with Miplyffa generating $17.1M in net revenue.

Product Launch and Sales

The company is enjoying a nice sales ramp for Miplyffa, which is a key driver of the stock in the near term.

Strategic Positioning

Zevra Therapeutics has successfully transitioned into a commercial-stage rare disease company with multiple levers for further long term value creation.

Negative Factors

Product Performance

Olpruva's revenue remains modest despite a strategy focused on targeting adult patients with reimbursement challenges.

Transparency

ZVRA did not specifically provide an updated cash runway, but said it has 'ample resources and financial flexibility to execute on our strategic priorities independent from the capital markets.'

Zevra Therapeutics Business Overview & Revenue Model

Company Description

Zevra Therapeutics (ZVRA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare diseases and unmet medical needs. The company operates within the healthcare sector, specifically targeting the pharmaceutical industry. Its core products include a pipeline of drug candidates in various stages of clinical development, aiming to address serious health conditions where existing treatments are inadequate.

How the Company Makes Money

Zevra Therapeutics generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company's revenue streams include licensing agreements, where it partners with larger pharmaceutical companies to co-develop and distribute its therapies, thereby earning milestone payments and royalties on sales. Additionally, Zevra may engage in strategic collaborations and partnerships that provide funding for research and development activities. The company also focuses on obtaining regulatory approval for its therapies, which enables it to market and sell these products directly, further contributing to its revenue growth.

Zevra Therapeutics Financial Statement Overview

Summary

Zevra Therapeutics faces significant financial challenges, including a high debt-to-equity ratio, negative net profit margin, and negative free cash flow, indicating financial instability. Despite strong gross margins, the reliance on external financing and negative profitability metrics pose substantial risks.

Income Statement

Zevra Therapeutics shows a mixed performance in its income statement. The TTM (Trailing-Twelve-Months) gross profit margin is strong at 78.87%, indicating efficient cost management relative to revenue. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -226.63% and a negative EBIT margin of -177.09%. Revenue growth is inconsistent, with a notable increase in the latest period but a decline in previous years. The negative EBITDA margin of -165.97% further highlights operational challenges.

Balance Sheet

The balance sheet of Zevra Therapeutics reflects a high debt-to-equity ratio of 1.51, suggesting significant leverage and potential financial risk. The equity ratio is low at 23.76%, indicating limited equity financing. Return on equity is negative at -224.27%, reflecting ongoing losses. Despite these challenges, the company maintains a reasonable level of cash and short-term investments, which provides some liquidity cushion.

Cash Flow

Cash flow analysis reveals significant challenges for Zevra Therapeutics. The operating cash flow to net income ratio is 0.67, indicating that cash flow from operations is insufficient to cover net losses. Free cash flow is negative, and the free cash flow to net income ratio is 0.67, highlighting cash constraints. The company relies heavily on financing activities to support operations, which could pose risks if external funding becomes less accessible.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	23.61M	27.46M	10.16M	28.65M	13.29M
Gross Profit	16.20M	24.52M	9.94M	26.59M	11.98M
EBITDA	-76.40M	-48.60M	-25.53M	-7.89M	-5.43M
Net Income	-105.51M	-46.05M	-26.77M	-8.55M	-12.76M
Balance Sheet
Total Assets	178.13M	172.33M	115.53M	132.94M	11.21M
Cash, Cash Equivalents and Short-Term Investments	69.50M	43.05M	82.85M	112.35M	4.21M
Total Debt	60.30M	43.77M	14.12M	1.59M	70.35M
Total Liabilities	138.46M	110.46M	29.72M	5.82M	77.62M
Stockholders Equity	39.67M	61.86M	85.81M	127.12M	-66.41M
Cash Flow
Free Cash Flow	-69.67M	-33.83M	-18.81M	10.34M	-1.97M
Operating Cash Flow	-69.67M	-33.53M	-18.72M	10.44M	-1.94M
Investing Cash Flow	-22.16M	-17.39M	-36.72M	-15.52M	-33.00K
Financing Cash Flow	82.11M	28.46M	8.35M	113.11M	2.74M

Zevra Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.23
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZVRA, the sentiment is Neutral. The current price of 11.23 is below the 20-day moving average (MA) of 11.27, above the 50-day MA of 9.84, and above the 200-day MA of 8.53, indicating a neutral trend. The MACD of 0.63 indicates Positive momentum. The RSI at 53.62 is Neutral, neither overbought nor oversold. The STOCH value of 11.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ZVRA.

Zevra Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZVRA	60 Neutral	$614.05M	―	-204.78%	―	44.92%	-40.06%
MAZE	59 Neutral	$720.46M	―		―	―	―
RLAY	57 Neutral	$630.92M	―	-45.46%	―	-78.26%	15.41%
UPB	57 Neutral	$718.15M	―		―	―	―
Sector *	52 Neutral	$7.63B	0.11	-62.96%	2.08%	16.16%	0.31%
OMER	40 Underperform	$210.35M	―	87.26%	―	―	-43.76%

Zevra Therapeutics Corporate Events

Zevra Therapeutics Elects New Directors at Annual Meeting

On May 29, 2025, Zevra Therapeutics held its Annual Meeting of Stockholders where Wendy Dixon, Ph.D., and Tamara A. Favorito were elected as directors. The meeting also saw the ratification of Ernst & Young LLP as the independent public accounting firm for the fiscal year ending December 31, 2025. The election process was marked by the disqualification of nominees proposed by stockholder Daniel J. Mangless due to non-compliance with legal requirements and company bylaws, ensuring the election of the company’s preferred candidates.

The most recent analyst rating on (ZVRA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Zevra Therapeutics stock, see the ZVRA Stock Forecast page.